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BACKGROUND: In high-volume processing environ-
ments, manual breakage of in-line closures can result in
repetitive strain injury (RSI). Furthermore, these clo-
sures may be incorrectly opened causing shear-induced
hemolysis. To overcome the variability of in-line closure
use and minimize RSI, Fresenius Kabi developed a
new in-line closure, the CompoFlow, with mechanical
openers.
STUDY DESIGN AND METHODS: The consistency of
the performance of the CompoFlow closure device was
assessed, as was its effect on component quality. A
total of 188 RBC units using CompoFlow blood bag
systems and 43 using the standard bag systems were
produced using the buffy coat manufacturing method.
Twenty-six CompoFlow platelet (PLT) concentrates and
10 control concentrates were prepared from pools of
four buffy coats. RBCs were assessed on Days 1, 21,
and 42 for cellular variables and hemolysis. PLTs were
assessed on Days 1, 3, and 7 for morphology, CD62P
expression, glucose, lactate, and pH. A total of 308 clo-
sures were excised after processing and the apertures
were measured using digital image analysis.
RESULTS: The use of the CompoFlow device signiﬁ-
cantly improved the mean extraction time with
0.46  0.11 sec/mL for the CompoFlow units and
0.52  0.13 sec/mL for the control units. The Compo-
Flow closures showed a highly reproducible aperture
after opening (coefficient of variation, 15%) and the
device always remained opened. PLT and RBC prod-
ucts showed acceptable storage variables with no dif-
ferences between CompoFlow and control.
CONCLUSIONS: The CompoFlow closure devices
improved the level of process control and processing
time of blood component production with no negative
effects on product quality.
M
any manual steps are performed by quali-
ﬁed staff during the processing of whole
blood collections for blood component
preparation. Some of these manual pro-
cessing steps, for example, those involving a pinch grip
posture, can lead to repetitive strain injuries (RSIs).1 In
particular, the opening of in-line breakaway closures,
whichinvolvesrepeatedgrippingandpinchingforces,can
lead to RSI. In addition, the current design of breakaway
closures involves the fracture of a hard plastic device and
the manual separation of the pieces to facilitate appropri-
atebloodﬂow.Thismaybeinconsistentlydone,leadingto
excessive shear stress on the red blood cells (RBCs) and
associated hemolysis.2 A new design of in-line closures
developed by Fresenius Kabi (Bad Homburg, Germany)
addresses the issues of both RSI and unanticipated
hemolysis through a change in the mechanism by which
the closures are opened. The new closure type consists of
a nonfrangible plastic plug in the tubing; a focused lateral
ABBREVIATIONS: PC(s) = platelet concentrate(s);
rRBC(s) = residual red blood cell(s); RSI = repetitive strain
injury; rWBC(s) = residual white blood cell(s).
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2240 TRANSFUSION Volume 50, October 2010force causes the plug to deform and collapse on itself
thereby opening a passage for the ﬂow of blood compo-
nents. In this study, the lateral pressure was applied by a
manual hand-held device; however, in its ﬁnal form the
hand-held opener is electronic and operated by the push
of a button. It is also possible to initiate the lateral force
necessary to open the plug using an automated extractor
(Compomat G5, Fresenius Kabi). This new closure design
may also achieve more consistent opening of in-line clo-
sures than current breakaway in-line closure designs.
The aim of this study was to understand whether the
conﬁguration of the new closure device had any effect on
blood component quality. Since shear stress can affect
platelet (PLT) activation levels3 and can result in RBC
damage,4,5 investigations focused on the quality of the cel-
lular blood components produced using the in-line clo-
sures. The consistency of the performance of the closure
device was also assessed.
MATERIALS AND METHODS
Blood component production
Blood was collected and processed according to standard
operating procedures at Canadian Blood Services’ devel-
opment laboratory. All blood donors provided signed
informed consent to participate in the study. Donors par-
ticipating in the study were deferred from the regional
blood donor pool for reasons other than their own health
(e.g.,traveldeferral).ThestudywasapprovedbyCanadian
Blood Services Research Ethics Board.
Whole blood units were collected using a quadruple
blood bag system (CompoFlow,T&B 450/450/450/450 mL
with in-line RBC ﬁlter and Composampler V, Fresenius
Kabi). For comparison, whole blood units were prepared
usingastandardFreseniusKabibloodbagsystemwiththe
same conﬁguration except for having traditional break-
away closures rather than CompoFlow closures. Whole
blood was stored on cooling trays overnight. All units were
processed for buffy coats using an automatic extractor
(Compomat G4, Fresenius Kabi) and the settings recom-
mended by the manufacturer. Extraction times were
obtained from the electronic record of extraction for each
unit. CompoFlow closures were opened, using a purpose-
built hand-held prototype tool. RBC ﬁltration times were
obtained manually using timers. PLT pools of four buffy
coats were made by the“train method.” Since CompoFlow
closures are not symmetrical, the docking practice for the
train was performed in a manner that placed like ends of
the buffy coat bags adjacent to each other, that is, top to
top or bottom to bottom. Thus, directional ﬂow would
occur either into the narrower opening ﬁrst, through the
wider side, into the next wide side, and out the second
narrow opening or vice versa. All products were stored for
the standard period under routine blood bank storage
conditions. PLT concentrates (PCs) were stored at 22°C in
a temperature-controlled incubator with agitation on a
ﬂatbed agitator (Helmer, Noblesville, IN). RBCs were
stored in a 4°C refrigerator for 42 days. Plasma was exam-
ined immediately after preparation for signs of visual
hemolysis and then frozen at -40°C. At the end of storage,
cellular products were assessed for sterility to ensure that
no contamination was introduced as a result of handling.
Closure evaluation
Each CompoFlow blood bag system has three in-line clo-
sures(Fig. 1).Allthreeoftheopenedclosureswereexcised
from the line for aperture assessment. Closures were
gently rinsed in saline followed by distilled water and let
dry prior to image analysis. Closures 1 and 2 were gener-
ally assessed within 48 hours of opening, but Closure 3
was not assessed until after Day 42 since it could not be
removed without compromising the RBC storage bag.
Aperture images were obtained with a digital camera
(QImaging Retiga 1300, Surrey, British Columbia, Canada)
attached to a macroscope (Wild-Leitz Apozoom, Heer-
brugg, Switzerland). Closures were positioned on a stage
such that the camera’s point of view was directed down
the lumen of the tubing. Magniﬁcation was kept constant
(zoom, 6.25). An internal standard consisting of a blunt-
ended needle tip was placed in each image to ensure that
the calibration was maintained. The mean pixel count of
the needle width was 99, ranging from 96 to 102, in all
images. Image analysis was conducted using computer
software (Adobe PhotoShop, Adobe Systems, Inc., San
Jose,CA)inwhichanareawasdelineatedthatrepresented
the minimum aperture of each opened closure. Pixel
countsweregeneratedtoprovidequantitationoftheaper-
ture area. The method was assessed for reproducibility by
measuring the same aperture 10 times with new place-
ment of the closure on the macroscope stand each time;
there was a high degree of reproducibility, with a coefﬁ-
cient of variance (CV) for the aperture area of 0.1%.
RBC evaluation
A sample from the RBCs before ﬁltration was collected
using a sampling device (VFE0000Y, Macopharma,
Mouvaux, France) attached by sterile docking. Completed
RBCsweresampledasepticallyusingtheportsonthebags
into ethylenediaminetetraacetic acid (EDTA) tubes (Vacu-
tainer, BD, Franklin Lakes, NJ) on Days 1, 21, and 42. A
hematology analyzer (Advia 120, Siemens AG, Munich,
Germany) was used to measure cell count and mean cor-
puscle volume (MCV). To obtain the total hemoglobin
(Hb) measurement, RBCs were diluted 1/1000 with Drab-
kin’s reagent (Sigma, St Louis, MO). For supernatant
Hb, RBCs were subjected to a double centrifugation
(2000 ¥ g for 10 min and resulting supernatant at
15,000 ¥ g for 15 min). The supernatant was diluted 1/5
with Drabkin’s reagent. Samples were read using a plate
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CA) at 540 nm. A ﬁve-point calibration curve was created
for each plate using a cyanmethemoglobin standard
(Stanbio Laboratory, Boerne, TX). Hematocrit (Hct) was
determined by collecting samples of RBCs in heparinized
microcapillary tubes (Fisher Scientiﬁc, Nepean, Ontario,
Canada), spinning in a microhematocrit centrifuge (IEC
MB, Damon/IEC Division, Needham Heights, MA) for 5
minutes and visually quantifying the percentage of RBCs
using a microcapillary reader (Damon/IEC Division).
Total Hb measurements were made with Drabkin’s assay
and Hct measurements were made using microcapillary
centrifugation because it has recently been shown that
theseassayscangivemorereliablemeasuresofthesevari-
ables than a hematology analyzer.6 Hemolysis was calcu-
lated according to the formula
% hemolysis 1 Hct supernatant Hb total Hb. =− ( )×
For a subset of randomly selected RBC units collected
with the CompoFlow bag set, on Days 1, 7, 14, 21, 35, and
42, blood gas metabolic measurements at 37°C (pH,
glucose, and lactate) were obtained using a blood gas ana-
lyzer (GEM Premier 3000, Instrumentation Laboratory,
Orangeburg, NY). For results exceeding the normal range
a 1:2 dilution in phosphate-buffered saline (PBS) of the
sample was made and the test was repeated. With the
exception of three samples, measurements occurred
within 10 minutes of dilution. For samples with pH lower
than detection level, measurements were performed
using a pH meter (benchtop model 8005, VWR Interna-
tional, Plainﬁeld, NJ) at room temperature. pH measure-
ments were converted to pH(37°C) using the pH
temperature correction equation recommended by
Ashwood and coworkers.7
PLT evaluation
PLT ability to swirl was assessed against direct light. A
four-point scoring system was used: maximum score was
given to the units with a deﬁned swirl and minimum score
to units with no swirl. All swirling assessments were per-
formed by the same individual to minimize reader vari-
ability. PCs were sampled aseptically using the ports on
the bags on Days 1, 3, and 7 of storage. PLT counts and
mean PLT volume were obtained after a 10-minute incu-
bationofthesampleinanEDTAVacutainertubeusingthe
hematology analyzer. PLT activation of this sample was
detected using a ﬂow cytometer (FACSCanto II, BD Bio-
sciences, San Jose, CA). PLTs were stained with ﬂuorescent
CD42a and CD62P antibodies (Immunotech, Marseille,
France). Fluorescent isotype antibodies were used for the
negative control. The PLT population was deﬁned based
on forward scatter and side scatter characteristics. Events
with higher ﬂuorescence than negative control were con-
sidered to be positive. Five-thousand events were col-
lected in duplicate for each sample. A PC sample was also
collected into a syringe for blood gas measurements at
Fig. 1. Schematic drawing of CompoFlow bag set depicting locations of the in-line closures: Closure 1 on the CPD/WB/BC bag, Clo-
sure 2 on the processing bag, and Closure 3 on the SAG-M/RBC bag. CPD = citrate-phosphate-dextrose;WB = whole blood; BC =
buffy coat; SAG-M = saline-adenine-glucose-mannitol.
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For blood gas measurements exceeding the normal range,
a 1:2 dilution in PBS of the sample was made and the test
was repeated. Samples were measured within 10 minutes
of dilution. PLT morphology was assessed by modiﬁed
Kunicki morphology scoring.8 The PC sample was ﬁxed
with an equal volume of 4% paraformaldehyde. Samples
were stored at room temperature and analyzed within 1
week by phase contrast microscopy at 1000¥ magniﬁca-
tion. One-hundred PLTs were counted and categorized by
shape as discoid, spiny sphere, or balloons. The morphol-
ogy score was calculated by multiplying the number of
discoid PLTs by 4, spiny spheres by 2, and balloons by 1
and then adding them together.
Plasma evaluation for residual RBCs
Plasma units that appeared slightly pink were assessed for
RBC content with a residual RBC (rRBC) enumeration
assay developed by Canadian Blood Services using the
Advia 120 CSF program (Siemens, Tarrytown, NY).9
Plasma was diluted 10 times in PBS and mixed with Advia
120 CSF reagent in a ratio of 1:1. After a 5- to 20-minute
incubation at room temperature and thorough mixing,
samples were analyzed using the Advia 120 CSF program
mode.
Residual white blood cell count
For RBCs and PCs, the presence of residual white blood
cells (rWBCs) was detected with a commercially available
kit (Leukocount, BD Biosciences). Brieﬂy, 100 mLo f
sample was added to a tube containing a known amount
of beads (Trucount, BD Biosciences). Leukocount reagent
(400 mL) was added to the agitated mixture and incubated
for 15 minutes in the dark. Flow cytometric analysis was
performed on 10,000 events. The absolute rWBC count
was calculated according to the manufacturer’s
instructions.
Statistical analysis
A comparison of the blood components produced using
CompoFlow bags versus standard bags was made at the
endofthestudy.ttestanalyses(bothpairedandunpaired)
were performed with computer software (Microsoft Excel,
Microsoft Corp., Redmond, WA; or Prism 3.0, GraphPad,
La Jolla, CA). Correlation analyses were performed with
Microsoft Excel. Analysis of variance (ANOVA) and corre-
sponding pairwise comparison posttests were performed
using an online tool for statistical computation (Vas-
sarStats Website for Statistical Computation, http://
faculty.vassar.edu/lowry/VassarStats.html).Apv alue of
less than 0.05 was accepted as indicating signiﬁcance.
RESULTS
A total of 188 blood collections were made with Compo-
Flow bag sets on 12 separate days and 43 collections on 3
separate days were made with the control bag sets. Forty
PCs were produced from CompoFlow collections and 10
PCs were produced from control collections.
Blood component volumes are summarized in
Table 1. CompoFlow had slightly lower buffy coat volumes
(p < 0.05, two-tailed t test) but at most, the true difference
between the means is tiny and uninteresting. All other
blood component volumes were not different between
CompoFlow and control.
CompoFlow closures
In total, 308 CompoFlow closures were excised from their
respective bags for analysis after blood component
production: 102 closures from the buffy coat bag (Closure
1), 101 closures from the processing bag (Closure 2), and
105 closures from the RBC storage bag (Closure 3). In no
case was a closure found to return to its original state after
opening, irrespective of elapsed time between opening
and analysis (1 to >42 days); once opened, the opening is
permanent.Imagesofclosuresweretakenfrombothsides
of each closure (Figs. 2A and 2B). The closure openings
were smaller at the “pointed” end (8.0  1.2 mm2;C V ,
15%) than at the “bottom” end (15.0  2.3 mm2; CV, 15%)
with a slightly skewed distribution for the opening area at
the bottom end (Fig. 2C). The area of the aperture at the
pointed end was approximately 38% that of the cross-
sectional area of the tubing (21  0.2 mm2). Correlation
statistics were therefore performed using the data from
the pointed end because this was felt to be the most rig-
orous challenge for the cells in terms of passing through
the aperture.
TABLE 1. Blood component volumes (mL)*
Bag system Whole blood RBC Plasma Buffy coat† Pooled PLTs
CompoFlow‡ 451  19 (245-543, 451) 256  19 (151-316, 256) 281  20 (180-336, 283) 50  2 (44-58, 50) 329  11 (301-351, 326)
Control§ 444  23 (300-453, 450) 253  16 (195-268, 254) 278  20 (189-308, 278) 51  3 (46-59, 50) 331  8 (321-345, 330)
* Data are expressed as mean  1 SD (range, median).
†p = 0.01, CompoFlow versus control.
‡ Whole blood, RBCs, plasma, and buffy coat, n = 188; pooled PLTs, n = 40.
§ Whole blood, RBCs, plasma, and buffy coat, n = 43; pooled PLTs, n = 10.
COMPOFLOW CLOSURES
Volume 50, October 2010 TRANSFUSION 2243Extraction and ﬁltration
The time required for extraction of the different compo-
nents on the Compomat G4 was monitored to determine
whether the CompoFlow closures affected the ﬂow rate
of the extraction. Extraction time was normalized against
the volume of the whole blood units. Units for which
the tubing was kinked during extraction or for which a
manual stop of the extraction process
was required were not included in the
analysis. Similarly the time required for
RBC ﬁltration was monitored and ﬁltra-
tion time was normalized against the
volume of the RBCs. Units for which
ﬁlters were not primed in the correct
orientation were not included in the ﬁl-
tration time analysis. Extraction time
was signiﬁcantly shorter with the Com-
poFlow bag sets (p = 0.01, two-tailed t
test). There was no difference in RBC
ﬁltration time detected between Com-
poFlow and control bag sets (Table 2).
There was no correlation between
the combined CompoFlow closure
aperture area of Closures 1 and 2 and
the total extraction time (r = 0.03,
n = 93). The CompoFlow closures do
not appear to limit the ﬂow during
extraction.
RBCs
Due to work scheduling, 23 RBC units
were sampled on Day 22 instead of Day
21 and 32 RBC units were sampled on
Day 43 instead of Day 42; the data from
these units were pooled with Day 21
and Day 42 data sets, respectively. The
ﬁrst batch of preﬁltration samples suf-
fered a sampling error; therefore, these
data were omitted from all analyses.
RBC count, Hb levels, and Hct de-
creased from the preﬁltration sample
to the postﬁltration sample (p < 0.01),
indicating that there was RBC loss
occurring during the ﬁltration process
as might be expected. RBC count, Hb
levels, and Hct stayed fairly consistent
thereafter (Table 3). This trend was
similar for both CompoFlow and
control samples and there was no dif-
ference between the two bag systems
for either RBC count or total Hb. The
Hct of the CompoFlow group was
slightly higher than that of the control
group (p < 0.01, two-factor ANOVA with
repeated measures on one factor), although this is not
clinically meaningful and statistical signiﬁcance was only
achieved because the data set had limited variability. A
different trend was noticed for RBC MCV (Table 3). As
expected the MCV was not different before and after RBC
ﬁltration. However, upon storage the MCV increased for
both CompoFlow and control samples (p < 0.01); this is
Fig. 2. CompoFlow image analysis. Representative images of opened CompoFlow clo-
sures looking down the lumen of the tubing at the pointed end of the closure (A) and
the bottom end of the closure (B).The black bar at the top left corner of each image
is the internal standard (width, 0.9 mm). Frequency histogram of closure aperture
area at the pointed end () and the bottom end ( ;C ) .
TABLE 2. Normalized extraction and RBC ﬁltration times (sec/mL)*
Bag system Extraction time† RBC ﬁltration time
CompoFlow‡ 0.46  0.11 (0.34-1.48, 0.44) 8.1  1.3 (4.0-13.4, 8.2)
Control§ 0.52  0.13 (0.42-1.12, 0.47) 7.8  1.1 (5.8-12.5, 7.6)
* Data are expressed as mean  1 SD (range, median).
†p = 0.01, CompoFlow versus control.
‡ Extraction time, n = 178; RBC ﬁltration time, n = 121.
§ Extraction time, n = 42; RBC ﬁltration time, n = 43.
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cient operation of the Na+/K+ pumps in cold storage.
RBC hemolysis measurements decreased slightly
after the ﬁltration step (Fig. 3), suggesting some loss of
supernatant Hb on the ﬁlter. Percent hemolysis
increased signiﬁcantly (p < 0.01) over storage but there
was no difference in percent hemolysis between Compo-
Flow and control samples (two-factor ANOVA with
repeated measures on one factor). It appears that the
CompoFlow closures do not negatively impact RBC
integrity any more than a correctly opened traditional
breakaway closure might. The European Council guide-
lines state that hemolysis must be less than 0.8% of RBC
mass10 and FDA guidance suggests that there be no more
than 1% hemolysis at the end of the storage period.11 One
CompoFlow RBC unit and one control RBC unit had
hemolysis levels greater than this with 1.086 and 0.984%
hemolysis, respectively. The relation-
ship between percent hemolysis and
the size of the CompoFlow aperture
was analyzed for the four RBC hemoly-
sis measurements (Day 1 before ﬁltra-
tion, Day 1 after ﬁltration, Day 21, and
Day 42) versus the aperture sizes of the
CompoFlow closures from the process-
ing bag (Closure 2) and the ﬁnal RBC
storage bag (Closure 3). There was no
correlation between the percent
hemolysis measurements and the
CompoFlow apertures for either of the
opened closures that the RBC pass
through during production.
Blood gas/electrolyte measure-
ments for a random subset of 10 Com-
poFlow RBC units are reported in
Table 4. pH decreased from Day 1 to
D a y1 4( p< 0.01) and remained constant for the remain-
der of the storage period whereas pO2 slowly increased
over the storage period (p < 0.001). Glucose levels
decreased from Day 1 to Day 14 and from Day 14 to Day
28 (p < 0.01). While not attaining signiﬁcance after Day
28, the glucose levels appeared to slowly continue their
downward trend to Day 42. Complementing the glucose
measurements, lactate levels increased from Day 1 to
Day 14 and from Day 14 to Day 28 (p < 0.01, one-way
ANOVA for ﬁve correlated samples), appearing to slowly
continue the upward trend to Day 42, although again not
signiﬁcant past Day 28. rWBC count for these units
ranged from 6360 to 199,538 rWBCs/unit, averaging
69,483  57,587 rWBCs/unit. This subset of RBCs met
AABB standards for rWBCs in leukoreduced RBCs
(<5 ¥ 106 WBCs/unit)12 as well as Council of Europe stan-
dards (<1 ¥ 106 WBCs/unit).10
TABLE 3. RBC variables*
Variable Before ﬁltration, Day 1
After ﬁltration
Day 1 Day 21 Day 42
RBC count (¥10
12/L)
CompoFlow† 6.9  0.4 (5.1-8.6, 6.9) 6.1  0.4 (4.0-6.9, 6.1) 6.2  0.5 (4.1-7.9, 6.2) 6.1  0.5 (4.0-8.2, 6.1)
Control‡ 6.9  0.3 (6.3-7.8, 7.0) 6.1  0.4 (5.4-6.9, 6.2) 6.0  0.4 (5.0-6.9, 5.9) 6.0  0.4 (5.3-6.8, 6.0)
Hb (g/L)
CompoFlow 215  11 (158-253, 216) 191  11 (127-214, 192) 195  17 (126-257, 193) 192  17 (127-258, 191)
Control 217  8 (195-234, 218) 191  9 (167-206, 192) 189  14 (159-235, 188) 189  10 (164-219, 189)
Hct (L/L)
CompoFlow 0.67  0.03 (0.49-0.80, 0.68) 0.60  0.03 (0.39-0.66, 0.60) 0.60  0.05 (0.39-0.80, 0.60) 0.60  0.05 (0.39-0.79, 0.59)
Control 0.67  0.02 (0.60-0.72, 0.68) 0.59  0.02 (0.50-0.63, 0.60) 0.58  0.04 (0.49-0.68, 0.58) 0.58  0.03 (0.50-0.64, 0.59)
MCV (fL)
CompoFlow 97  4 (87-107, 97) 98  4 (87-107, 98) 100  4 (89-110, 100) 102  4 (90-112, 102)
Control 95  4 (86-104, 96) 97  4 (85-105, 97) 99  4 (87-106, 100) 101  5 (88-110, 101)
* Data are expressed as mean  1 SD (range, median).
† CompoFlow before ﬁltration Day 1, n = 172; after ﬁltration Day 1, Day 21, and Day 42, n = 188.
‡ Control before ﬁltration Day 1, n = 42; after ﬁltration Day 1, Day 21, and Day 42, n = 43.
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Fig. 3. Mean percent RBC hemolysis of RBCs on Day 1 (before and after ﬁltration),
Day 21, and Day 42 for CompoFlow (, —) and control (, - - -). CompoFlow,
n = 188, except before ﬁltration Day 1, n = 171; control, n = 43.
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The units prepared during the ﬁrst 4 collection days did
not use the ﬁnal centrifuge packing scheme and it was
deemed that due to the high sensitivity of PLTs to shear
stress, this may lead to a disturbance of the PLTs. The PCs
from these ﬁrst four collections were therefore omitted
from the PLT analysis. Of 26 CompoFlow PCs, two PCs
contained PLTs originating from donors who had ingested
acetylsalicylic acid (in one of four buffy coats in the pool),
onePCwasmadewithtwoslightlylow-volumebuffycoats
(44 mL each), and one PC exceeded the 28-hour process-
ing time by 10 minutes. These units were included in the
ﬁnal analysis. Of these, 4 units were not sampled on Day 3
for reasons of logistics.
Measurements of PC quality variables are listed in
Table 5.While PLT surface expression of CD62P increased
signiﬁcantly (p < 0.01) with time of storage reﬂecting the
development of the PLT storage lesion, there was no dif-
ference detected between CompoFlow and control PCs.
CD62P expression data were analyzed together with the
size of the aperture of the buffy coat closure openings
(Closure 1) to determine whether a correlation between
these measurements might exist. It was hypothesized
that a smaller aperture size might result in increased PLT
activation. Since the PLTs pass through one or three of
these buffy coat closure openings as the train is pooled
into one larger unit, the correlation was determined for
both the mean and the minimum aperture areas of these
three closures. There was no correlation between CD62P
expression and the CompoFlow opening mean aperture
or between CD62P expression and the CompoFlow
opening minimum aperture (n = 22). Morphology scores
decreased signiﬁcantly over the storage period as
expected (p < 0.01) and there was no difference between
CompoFlow or control PCs. As for CD62P expression,
there was no correlation between morphology and the
CompoFlow aperture area. Visual swirl, which like mor-
phology scoring, assesses PLT shape change, also
decreased over time (p < 0.01). PC pH followed a charac-
teristic trend of increasing to Day 3 and then decreasing
to Day 7. The differences between days were signiﬁcant
TABLE 4. RBC blood gas/electrolytes*
Variable Day 1 Day 14 Day 28 Day 35 Day 42
pH 6.75  0.10
(6.55-6.88, 6.76)
6.41  0.09
(6.17-6.51, 6.43)
6.32  0.15
(6.16-6.56, 6.28)
6.36  0.13
(6.10-6.52, 6.39)
6.35  0.07
(6.25-6.44, 6.33)
pO2 (mmHg) 32  11
(21-51, 28)
45  14
(33-72, 38)
65  27
(43-123, 54)
76  29
(51-141, 62)
86  38
(52-164, 71)
Glucose (mmol/L) 29  4
(23-35, 29)
24  2
(19-27, 24)
19  2
(15-21, 20)
18  2
(13-20, 19)
17  2
(11-19, 18)
Lactate (mmol/L) 6  1
(4-7, 5)
13  2
(10-17, 13)
17  2
(14-20, 17)
19  4
(15-26, 18)
21  4
(16-27, 19)
* Data are reported as mean  1 SD (range, median), n = 10.
TABLE 5. PLT quality variables on Days 1, 3, and 7 of storage*
Variable
CompoFlow† Control‡
Day 1 Day 3 Day 7 Day 1 Day 3 Day 7
PLTs/unit (¥10
9) 300  49
(235-397, 288)
269  46
(199-369, 263)
286  52
(204-381, 289)
293  51
(215-389, 295)
273  50
(190-342, 282)
276  51
(199-354, 284)
MPV (fL) 7.7  0.5
(7.1-8.9, 7.7)
8.4  0.4
(7.7-9.2, 8.4)
8.3  0.4
(7.6-9.1, 8.3)
7.9  0.4
(7.2-8.4, 8.0)
8.5  0.4
(7.9-9.4, 8.4)
8.3  0.3
(7.8-8.8, 8.2)
%CD62P expression 16  6
(6.3-34.2, 17.4)
18  5
(9.3-27.2, 17.8)
33  7
(18.5-44.0, 32.4)
16  4
(10.1-19.7, 17.0)
21  6
(13.3-34.5, 20.1)
34  6
(27.4-46.1, 32.9)
CD62P mean
ﬂuorescence
1021  269
(664-1932, 1019)
1549  357
(988-2258, 1520)
2038  453
(1347-3291, 2076)
957  195
(738-1215, 888)
1967  612
(1228-2951, 1759)
2162  392
(1851-3110, 1971)
Morphology 348  15
(317-368, 351)
328  12
(299-341, 329)
292  19
(266-337, 291)
352  9
(341-370, 348)
327  22
(293-357, 328)
297  18
(277-329, 299)
Swirl 4.0  0.1
(3.5-4.0, 4.0)
3.5  0.3
(3.0-4.0, 3.5)
2.8  0.3
(2.5-3.0, 3.0)
4.0  0.0
(4.0-4.0, 4.0)
3.4  0.3
(2.5-3.5, 3.5)
2.9  0.5
(1.5-3.0, 3.0)
pH 7.08  0.03
(7.00-7.14, 7.08)
7.32  0.03
(7.28-7.37, 7.32)
7.25  0.05
(7.14-7.36, 7.26)
7.08  0.02
(7.04-7.12, 7.08)
7.32  0.03
(7.27-7.36, 7.32)
7.24  0.05
(7.17-7.33, 7.23)
Glucose (mmol/L) 18.8  1.3
(16.7-22.5, 18.9)
17.1  0.9
(15.3-18.8, 17.0)
14.6  1.1
(12.4-16.5, 14.4)
18.3  0.9
(17.0-19.3, 18.5)
16.6  0.8
(15.2-17.6, 16.9)
13.8  1.2
(11.9-15.9, 13.9)
Lactate (mmol/L) 7.9  0.8
(6.1-10.5, 7.9)
9.6  0.7
(7.9-10.6, 9.7)
14.8  1.0
(13.6-17.4, 14.5)
7.7  0.6
(6.8-8.5, 7.7)
9.4  0.5
(8.9-10.4, 9.3)
14.5  0.7
(13.0-15.6, 14.6)
* Data are expressed as mean  1 SD (range, median).
† CompoFlow Day 1 and Day 7, n = 26; Day 3, n = 22.
‡ Control, n = 10.
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control testing requirement that the pH remain within
the range 6.4 to 7.4. Glucose decreased signiﬁcantly over
the days of storage and, correspondingly, lactate concen-
trations increased signiﬁcantly throughout storage
(p < 0.01). For all of the PLT quality variables measured,
there was no measurable difference between CompoFlow
and control PCs (multifactorial ANOVA and Tukey’s
“honestly signiﬁcant difference” pairwise comparisons
test).
A randomly selected subset (n = 10) of the Compo-
Flow PC units was examined for rWBC content. It was
expected that the amount of WBC contamination in the
units would be low since all units were subjected to leu-
koreduction via ﬁltration. The rWBC count on Day 1 was
5805  5450WBCs/unit with a range of 0 to 15,623WBCs/
unit.This subset of PCs met AABB standards for rWBCs in
pooled, leukoreduced PCs (<5 ¥ 106 WBCs)12 as well as
Council of Europe standards (<0.2 ¥ 106WBCs/single-unit
equivalent).10
Plasma
Seven“pink” plasma units were selected for measurement
of RBC contamination (rRBCs) and Hb content. These
plasma units did have RBCs settling out in the tubing, but
with the exception of possibly 1 unit, these units were not
sufﬁciently“red”tohavebeenﬂaggedinaroutineproduc-
tion environment. rRBC content in these units ranged
from 0.25 ¥ 109 to 10 ¥ 109 rRBCs/L (75 ¥ 106 to 2552 ¥ 106
rRBCs/unit) with a range of 0.37 to 1.48 g/L Hb. With the
exception of 1 unit, these plasma units met the Council of
Europe speciﬁcations for rRBCs (<6.0 ¥ 109/L).
None of the PCs or RBCs were contaminated with
bacteriaasdeterminedusingan8-mLinoculumofsample
inanaerobicbottleoftheBacT/ALERTbacterialdetection
system immediately after completion of the storage
period.
DISCUSSION
The CompoFlow blood bag system introduces a new
approach to in-line blood bag closures with a design that
departs substantially from the currently used breakaway
closures. In this study CompoFlow closures were opened
by a hand-held mechanical prototype device, that applied
pressure on the tubing external to the closure. Although
not tested in this study, CompoFlow closures are designed
to be opened with an automated device. In its ﬁnal form
forthemarketplace,thedeviceopenerwillbeahand-held
electronic device or will be integral to the semiautomated
extractor.
Digital image analysis indicated that the CompoFlow
closures provided an aperture that displayed a fairly
reproducible cross-sectional area (CV, 15%). This opening
was similar in size whether measured within a couple of
days of opening the in-line closure or whether measured
after 6 weeks of opening. It must be noted that the cross-
sectional area measured at the pointed end of the closure
with our macroscope setup is only an approximation of
the actual cross-sectional area. The reason for this is that
the aperture outline for the images taken at the pointed
end of the closure is drawn in a single plane; however, the
outline in fact represents a line that travels in multiple
planes. Restricted blood ﬂow with the potential for
disruption of cellular components is possible if a standard
breakaway closure is improperly opened by not being
broken completely. A design feature of the CompoFlow
opening devices is that once pressure is initiated, the
clamping motion must reach a threshold distance before
the device will disengage from the tubing. In this way,
partial opening of the CompoFlow closures is prevented.
In addition to the observation that CompoFlow clo-
sures do not appear to be limiting ﬂow during extraction
as determined through correlation statistics of extraction
time versus aperture size, extraction times using the
CompoFlow bag system were signiﬁcantly shorter than
those of standard bag sets. For a unit of 450 mL of whole
blood the mean extraction time using CompoFlow clo-
sures would be 3 minutes 27 seconds whereas using
standard breakaway closures the extraction time of a
450-mL whole blood unit would average 3 minutes
54 seconds. This corresponds to a decrease of approxi-
mately 12% in processing time for the extraction step.
Over the course of a day in a large blood center, this dif-
ference has the potential to translate into a signiﬁcant
gain in production efﬁciency.
RBCs are subjected to various mechanical forces as
well as nonmechanical stimuli during processing, which
can lead to increased hemolysis. Some of these stimuli
include incorrect anticoagulant ratios, passage through
partially opened transfer tube closures, temperature ﬂuc-
tuations, turbulence with rapid mixing, passage past the
edges of kinked tubing, resuspension of cell pellets, and
passage through ﬁlters.13 In this study, passage of RBCs
past CompoFlow closures did not appear to expose RBCs
to increased damaging shear forces or turbulence as there
was no difference in hemolysis between CompoFlow and
control units. A small amount of RBC hemolysis did con-
tinue over time in both CompoFlow and control units as is
known to occur in storage but on Day 42 both groups
averaged less than 0.3% hemolysis, which is well within
both the recommended American and the recommended
European Guidelines.11
PLTs also respond to the forces and conditions they
encounter during processing. PLTs become partially acti-
vated as determined by activation of GPIIbIIIa receptors
and expression of the degranulation marker CD62P
during those processing steps that occur after the initial
phlebotomy of the blood.14 In the study by Metcalfe and
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tive because they were able to identify signiﬁcant differ-
ences in PLT activation between different PLT production
methods. Here we report no difference in CD62P between
PLTsproducedeitherwithCompoFloworwithcontrolbag
systemseitheronthedayofproductionorafterstoragefor
3 and 7 days. Other PLT quality measures, pH, swirl, mor-
phology, glucose, and lactate, similarly mirrored a lack of
difference between CompoFlow and control. The aper-
tures formed by the CompoFlow closures do not appear to
cause areas of turbulence or shear stress that increase PLT
activation compared to breakaway closures.
CompoFlow closures impart an ergonomic system for
opening in-line closures which result in stable and repro-
ducible apertures. Cellular products produced using
CompoFlowbagsystemsdonotappeardifferentinquality
from those produced using standard breakaway closures
and they meet the requirements of American and Euro-
pean standard setting bodies.
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